Department of General Surgery, Zhejiang University, School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China.
Department of Thoracic Surgery, Zhejiang University, School of Medicine, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China.
Ann Surg Oncol. 2023 Sep;30(9):5447-5449. doi: 10.1245/s10434-023-13512-5. Epub 2023 Jun 7.
Facing the 0.7-22% incidence rate of hepatocellular carcinoma (HCC) with inferior vena cava tumor thrombus (IVCTT), there are usually no obvious symptoms and signs when the tumor thrombus completely blocks the IVCTT in the early stage.1.J Gastroenterol. 29:41-46;2.Hepatogastroenterology. 41:154-157;3.Clin Cardiol. 19:211-213; Once diagnosed, it is the end-stage manifestation without unified treatment for HCC with IVCTT, bringing poor prognosis. Without active treatment, the median survival time is only 3 months. Previous scholars believed that patients with IVCTT should not adopt active surgical treatment. With the advance of technology, active surgical treatment has significantly lengthened the survival time with IVCTT.4.Ann Surg Oncol. 20:914-22;5.World J Surg Oncol. 11:259;6.Hepatogastroenterology. 58:1694-1699; However, for patients with HCC and IVCTT, open surgery was always selected in the past by opening the diaphragm through the combined thoracoabdominal incision to block the superior and subhepatic vena cava, leading long incision and huge trauma. With the development of minimally invasive techniques, laparoscopy thoracoscopy has showed great advantages in the treatment of HCC with IVCTT. A patient underwent laparoscopic with thoracoscopic resection of tumor and cancer thrombectomy after neoadjuvant therapy and then survived after follow-up.7.Ann Surg Oncol. 29:5548-5549 Therefore, it used as a first reported case of robot-assisted laparoscopic with thoracoscopic treatment of HCC complicated inferior vena cava cancer thrombectomy.
A 41-year-old man had a liver space-occupying lesion discovered during his medical examination 2 months ago. The diagnosis of HCC with IVCTT was confirmed by enhanced CT and biopsy specimen in the first hospitalization. A combination of TACE, targeted therapy, and immunotherapy plan was applied for the patient after multidisciplinary treatment (MDT). Specifically, Lenvatinib was taken orally 8 mg daily and 160 mg of toripalimab was given intravenously every 3 weeks. His reexamination CT showed that the tumor was more advanced after 2 months of treatment. The surgical operation was performed based on comprehensive consideration. The patient was placed in the left lateral decubitus position, and a thoracoscopic prefabricated the inferior vena cava above diaphragm blocking device was pulled out of the incision. The patient was switched to a supine position with the head of the bed raised 30 degrees. The gallbladder was removed first after entering the abdominal cavity, then prefabricated first hilar blocking band. Sterile rubber glove edges and hemo-lock were used to fabricate the blocking device. The novel hepatic inflow occlusion device is a safe, reliable, and convenient technique that is associated with favorable perioperative outcomes and low risk of conversion.8.Surg Endosc. 34:2807-2813 The liver along the middle hepatic vein was cut to expose the anterior wall of the inferior vena cava, then prefabricated posterior inferior vena cava blocking belt and right hepatic vein blocking belt. Finally, the first portal of liver, right hepatic vein, retrohepatic inferior vena cava, and inferior vena cava above diaphragm were blocked in sequence, so that accomplishing tumor resection and thrombectomy of inferior vena cava. It should be emphasized that before the inferior vena cava is completely sutured, the retrohepatic inferior vena cava blocking device should be released to allow blood flow to flush the inferior vena cava. Moreover, transesophageal ultrasound is required to real-time monitor inferior vena cava blood flow and IVCTT. Some images of the operation are shown in Fig. 1. Fig. 1 (a) Layout of the trocar. ①Make a 3cm small incision between the right anterior axillary line and the midaxillary line, parallel to the fourth and fifth intercostal spaces; a puncture hole in the next intercostal space for endoscope; ②2cm above the intersection of umbilicus horizontal line and axillary front line; ③Intersection of right clavicular midline and umbilical horizontal line; ④Superior margin of umbilicus; ⑤The midpoint of '④ & ⑥'; ⑥2cm below the intersection of left clavicular midline and left costal margin. (b) Prefabricated the inferior vena cava blocking device above diaphragm by thoracoscopic. (c) The smooth tumor thrombus protruding into the inferior vena cava RESULTS: It took 475 min to finish the operation, and the loss of blood was estimated as 300 ml. The patient was discharged from hospital 8 days after the operation without postoperative complication. HCC was confirmed by postoperative pathology.
Robot surgical system reduces the limitations of laparoscopic surgery by offering a stable three-dimensional view, 10-times-enlarged image, restored eye-hand axis, and excellent dexterity with the endowristed instruments, which has several advantages over open operation such as diminished blood loss, reduced morbidity, and shorter hospital stay.9.Chirurg. 88:7-11;10.BMC Surg. 11:2;11.Minerva Chir. 64:135-146; Furthermore, it could favor the operative feasibility of difficult resections reducing the conversion rate and playing a role to extend the indications of liver resection to minimally invasive approaches. It may provide new curative options in patients deemed inoperable with conventional surgery, such as HCC with IVCTT.12.Biosci Trends. 16:178-188;13.J Hepatobiliary Pancreat Sci. 29:1108-1123.
面对肝细胞癌(HCC)伴下腔静脉癌栓(IVCTT)的 0.7-22% 的发病率,当肿瘤栓子完全阻塞 IVCTT 时,早期通常没有明显的症状和体征。1.J Gastroenterol. 29:41-46;2.Hepatogastroenterology. 41:154-157;3.Clin Cardiol. 19:211-213; 一旦诊断出该疾病,即处于终末期表现,没有统一的 HCC 伴 IVCTT 治疗方法,预后较差。未经积极治疗,中位生存时间仅为 3 个月。以前的学者认为,IVCTT 患者不应采用积极的手术治疗。随着技术的进步,积极的手术治疗显著延长了 IVCTT 患者的生存时间。4.Ann Surg Oncol. 20:914-22;5.World J Surg Oncol. 11:259;6.Hepatogastroenterology. 58:1694-1699; 然而,过去对于 HCC 和 IVCTT 患者,总是通过经胸腹联合切口切开膈肌来阻断肝上下腔静脉,导致长切口和巨大创伤,选择开腹手术。随着微创技术的发展,腹腔镜胸腔镜在 HCC 伴 IVCTT 的治疗中显示出了巨大的优势。一名患者在新辅助治疗后接受了腹腔镜与胸腔镜下肿瘤切除和癌栓取栓治疗,随访后存活下来。7.Ann Surg Oncol. 29:5548-5549 因此,这是首例机器人辅助腹腔镜与胸腔镜治疗 HCC 合并下腔静脉癌栓的报道。
一名 41 岁男性在 2 个月前的体检中发现肝脏占位性病变。第一次住院时通过增强 CT 和活检标本确诊 HCC 伴 IVCTT。在多学科治疗(MDT)后,为患者应用了 TACE、靶向治疗和免疫治疗方案。具体来说,每天口服乐伐替尼 8mg,每 3 周静脉注射 160mg 替雷利珠单抗。他在接受治疗 2 个月后的复查 CT 显示肿瘤更严重。在综合考虑后进行手术。患者取左侧卧位,将预先制作好的下腔静脉膈上阻断器从切口拉出。患者改为仰卧位,床头抬高 30 度。进入腹腔后首先切除胆囊,然后预先制作第一肝门阻断带。无菌橡胶手套边缘和血管锁用于制作阻断器。新型肝血流阻断装置是一种安全、可靠、方便的技术,具有良好的围手术期结果和低转化风险。8.Surg Endosc. 34:2807-2813 沿中肝静脉切断肝脏,暴露下腔静脉前壁,然后预先制作下腔静脉后、下腔静脉右支和肝静脉阻断带。最后,依次阻断第一肝门、右肝静脉、肝后下腔静脉和膈上下腔静脉,完成肿瘤切除和下腔静脉癌栓取栓。需要强调的是,在下腔静脉完全缝合之前,应释放肝后下腔静脉阻断器,以使下腔静脉血流冲洗。此外,需要经食管超声实时监测下腔静脉血流和 IVCTT。图 1 显示了一些手术图像。图 1(a)套管位置图。①在右前腋前线与腋中线之间的第 4-5 肋间作 3cm 小切口,下一肋间作内镜穿刺孔;②在脐与腋前线水平的交点上方 2cm;③锁骨中线与脐水平线的交点;④脐上缘;⑤④和⑥的中点;⑥左锁骨中线与左肋缘交点下 2cm。(b)胸腔镜下制作膈上腔静脉阻断器。(c)光滑的肿瘤栓子突出进入下腔静脉。
手术用时 475min,估计失血量 300ml。术后 8 天患者出院,无术后并发症。术后病理证实为 HCC。
机器人手术系统通过提供稳定的三维视图、10 倍放大的图像、恢复的眼手轴和优秀的手腕器械灵巧性,克服了腹腔镜手术的局限性,与开腹手术相比具有出血量少、并发症少、住院时间短等优点。9.Chirurg. 88:7-11;10.BMC Surg. 11:2;11.Minerva Chir. 64:135-146; 此外,它有利于困难切除的手术可行性,降低转化率,并在微创方法中发挥作用,将肝切除术的适应证扩展到传统手术之外,例如 HCC 伴 IVCTT。12.Biosci Trends. 16:178-188;13.J Hepatobiliary Pancreat Sci. 29:1108-1123.